Hangzhou NeU Biosciences

Hangzhou NeU Biosciences is a biotechnology company focused on the discovery and development of next-generation molecular glue degraders to treat cancer and autoimmune diseases. The company utilizes its proprietary NeU-Glue platform, which integrates high-throughput screening, structural biology, and artificial intelligence to identify small molecules that induce the degradation of previously undruggable proteins. Their current pipeline includes programs targeting Casein kinase 1 alpha and GSPT1 for hematological malignancies and solid tumors. NeU Biosciences aims to overcome the limitations of traditional inhibitors by leveraging the body's natural protein disposal system to eliminate disease-causing proteins.